PE20160285A1 - Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos. - Google Patents
Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos.Info
- Publication number
- PE20160285A1 PE20160285A1 PE2016000265A PE2016000265A PE20160285A1 PE 20160285 A1 PE20160285 A1 PE 20160285A1 PE 2016000265 A PE2016000265 A PE 2016000265A PE 2016000265 A PE2016000265 A PE 2016000265A PE 20160285 A1 PE20160285 A1 PE 20160285A1
- Authority
- PE
- Peru
- Prior art keywords
- rebamipide
- rebamipida
- propharmacs
- novelty
- preparation
- Prior art date
Links
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- -1 4-chlorobenzoylamino Chemical group 0.000 abstract 4
- 229950004535 rebamipide Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000005494 xerophthalmia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Abstract
La presenten invencion se dan a conocer un profarmaco de rebamipida novedoso de formula (I), un metodo para preparar el mismo y el uso del mismo. Ademas, se proporciona una composicion farmaceutica que comprende el profarmaco de rebamipida novedoso como el principio activo. El profarmaco de rebamipida tiene una tasa de absorcion aumentada 25 veces en comparacion con la propia rebamipida, y puede aplicarse a la profilaxis cronica, xeroftalmia, cancer, osteoartritis, artritis reumatoide u obesidad. Donde: X es O, N o S, Y es alquilo C1-C6, etc. Son compuestos preferidos: 2-(4-clorobenzoilamino)-3-(2-oxo-1,2-dihidroquinolin-4-il)propianato de metilo; 2-(4-clorobenzoilamino)-3-(2-oxo-1,2-dihidroquinolin-4-il)propianato de etilo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120068394 | 2012-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160285A1 true PE20160285A1 (es) | 2016-04-27 |
Family
ID=49783488
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014002534A PE20150904A1 (es) | 2012-06-26 | 2013-06-26 | Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos |
| PE2016000265A PE20160285A1 (es) | 2012-06-26 | 2013-06-26 | Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014002534A PE20150904A1 (es) | 2012-06-26 | 2013-06-26 | Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11420963B2 (es) |
| EP (1) | EP2865669B1 (es) |
| JP (1) | JP6032451B2 (es) |
| KR (1) | KR101452277B1 (es) |
| CN (1) | CN104662004B (es) |
| AP (1) | AP2015008233A0 (es) |
| AR (1) | AR097226A1 (es) |
| AU (1) | AU2013281442B2 (es) |
| BR (1) | BR112014032627A8 (es) |
| CA (1) | CA2877853C (es) |
| CL (1) | CL2014003496A1 (es) |
| CO (1) | CO7240352A2 (es) |
| ES (1) | ES2875863T3 (es) |
| IL (1) | IL236479A0 (es) |
| MA (1) | MA37676B1 (es) |
| MX (1) | MX2015000023A (es) |
| NZ (1) | NZ704023A (es) |
| PE (2) | PE20150904A1 (es) |
| PH (1) | PH12015500172B1 (es) |
| RU (1) | RU2612509C2 (es) |
| SA (1) | SA113340675B1 (es) |
| SG (1) | SG11201408711PA (es) |
| TW (1) | TWI483727B (es) |
| UA (1) | UA113990C2 (es) |
| UY (1) | UY34882A (es) |
| WO (1) | WO2014003424A1 (es) |
| ZA (1) | ZA201500450B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| WO2016108319A1 (ko) * | 2015-01-02 | 2016-07-07 | 삼진제약 주식회사 | 신규 레바미피드 전구체의 염 및 이의 용도 |
| KR20170094584A (ko) * | 2016-02-11 | 2017-08-21 | 삼진제약주식회사 | 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물 |
| KR102190019B1 (ko) * | 2018-10-23 | 2020-12-15 | 삼진제약주식회사 | 쇼그렌 증후군 예방 또는 치료용 조성물 |
| EP3797773A1 (en) * | 2019-09-03 | 2021-03-31 | Square Power Ltd | Rebamipide for use in prophylaxis and treatment of cancer |
| ES2913792T3 (es) * | 2019-09-03 | 2022-06-06 | Square Power Ltd | Rebamipida para uso en la profilaxis y el tratamiento de la enfermedad celíaca |
| CN111595985B (zh) * | 2020-07-09 | 2022-03-29 | 苏州正济药业有限公司 | 一种用hplc测定瑞巴派特有关物质的分析方法 |
| CN121039146A (zh) | 2023-04-27 | 2025-11-28 | 伊姆霍特克斯有限公司 | 作为nod2激动剂的去胞壁酰肽二酸及其用途 |
| WO2024224093A1 (en) | 2023-04-27 | 2024-10-31 | Imhotex Limited | Desmuramylpeptide dieesters as nod2 agonists and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI80022C (fi) | 1982-07-05 | 1990-04-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat. |
| JPS6019767A (ja) | 1983-07-11 | 1985-01-31 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体を有効成分とする抗潰瘍剤 |
| JP3621463B2 (ja) * | 1995-04-26 | 2005-02-16 | 大塚製薬株式会社 | カルボスチリル誘導体ビスマス塩 |
| KR100669823B1 (ko) | 2001-02-20 | 2007-01-17 | 경동제약 주식회사 | 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체 |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| KR20040104020A (ko) | 2003-06-02 | 2004-12-10 | 진양제약주식회사 | 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제 |
| TWI363626B (en) * | 2004-11-15 | 2012-05-11 | Otsuka Pharma Co Ltd | Aqueous ophthalmic suspension of crystalline rebamipide |
| KR101098116B1 (ko) * | 2004-12-01 | 2011-12-26 | 오츠카 세이야쿠 가부시키가이샤 | 레바미피드의 개선된 제조 방법 |
| JP2008105970A (ja) | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
| WO2008074853A1 (en) * | 2006-12-21 | 2008-06-26 | Novartis Ag | Ophthalmic rebamipide solution |
| KR101032600B1 (ko) | 2008-08-11 | 2011-05-06 | 동우신테크 주식회사 | 고순도 레바미피드의 제조방법 |
| KR101182114B1 (ko) * | 2010-03-05 | 2012-09-12 | 한림제약(주) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 |
| CN102174015B (zh) * | 2011-03-07 | 2013-10-16 | 江西同和药业有限责任公司 | 瑞巴派特的精制方法 |
-
2013
- 2013-06-24 SA SA113340675A patent/SA113340675B1/ar unknown
- 2013-06-26 EP EP13809037.8A patent/EP2865669B1/en active Active
- 2013-06-26 AP AP2015008233A patent/AP2015008233A0/xx unknown
- 2013-06-26 US US14/411,390 patent/US11420963B2/en active Active
- 2013-06-26 ES ES13809037T patent/ES2875863T3/es active Active
- 2013-06-26 SG SG11201408711PA patent/SG11201408711PA/en unknown
- 2013-06-26 UA UAA201500494A patent/UA113990C2/uk unknown
- 2013-06-26 TW TW102122678A patent/TWI483727B/zh not_active IP Right Cessation
- 2013-06-26 KR KR1020130073535A patent/KR101452277B1/ko not_active Expired - Fee Related
- 2013-06-26 MX MX2015000023A patent/MX2015000023A/es unknown
- 2013-06-26 JP JP2015520012A patent/JP6032451B2/ja not_active Expired - Fee Related
- 2013-06-26 PE PE2014002534A patent/PE20150904A1/es not_active Application Discontinuation
- 2013-06-26 WO PCT/KR2013/005622 patent/WO2014003424A1/ko not_active Ceased
- 2013-06-26 NZ NZ704023A patent/NZ704023A/en not_active IP Right Cessation
- 2013-06-26 AR ARP130102268A patent/AR097226A1/es unknown
- 2013-06-26 MA MA37676A patent/MA37676B1/fr unknown
- 2013-06-26 PE PE2016000265A patent/PE20160285A1/es unknown
- 2013-06-26 UY UY0001034882A patent/UY34882A/es not_active Application Discontinuation
- 2013-06-26 AU AU2013281442A patent/AU2013281442B2/en not_active Ceased
- 2013-06-26 CN CN201380034373.4A patent/CN104662004B/zh not_active Expired - Fee Related
- 2013-06-26 CA CA2877853A patent/CA2877853C/en active Active
- 2013-06-26 BR BR112014032627A patent/BR112014032627A8/pt not_active Application Discontinuation
- 2013-06-26 RU RU2015102043A patent/RU2612509C2/ru active
-
2014
- 2014-12-22 CL CL2014003496A patent/CL2014003496A1/es unknown
- 2014-12-25 IL IL236479A patent/IL236479A0/en unknown
-
2015
- 2015-01-22 ZA ZA2015/00450A patent/ZA201500450B/en unknown
- 2015-01-26 CO CO15014548A patent/CO7240352A2/es unknown
- 2015-01-26 PH PH12015500172A patent/PH12015500172B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160285A1 (es) | Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos. | |
| PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
| UY35300A (es) | Formulación de combinación de dos compuestos antivirales | |
| EA201492287A1 (ru) | Дейтерированные производные руксолитиниба | |
| CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
| IN2014CN04530A (es) | ||
| PH12013501704A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| JO3453B1 (ar) | مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1 | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| PH12014500987A1 (en) | Neprilysin inhibitors | |
| ECSP13012958A (es) | Inhibidores de benzodioxano de la producción de leucotrieno. | |
| IN2014MN02106A (es) | ||
| PH12015500260A1 (en) | Neprilysin inhibitors | |
| BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica | |
| BR112013030391A2 (pt) | derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| EA201600394A1 (ru) | Трициклические соединения пиперидина | |
| SG194711A1 (en) | Processes for preparing inhibitors of the hepatitis c virus | |
| EA201500313A1 (ru) | Стабилизированная аморфная форма агомелатина, способ ее изготовления и фармацевтические композиции, ее содержащие |